Select a year:

4P-Pharma is attending JP Morgan Week 2023

We are pleased to attend JPM Week 2023 from January 9th to 11th in California, United States. Our CEO Revital Rattenbach is looking forward to seeing you in person at this significant networking event for our healthcare ecosystem. Meet her at the French Healthcare Corner during JPM week 2023.

Read More

Have a look at our first series of three company videos

4P-Pharma is pleased to share with you a series of three videos produced in collaboration with Entreprendre magazine in order to highlight innovative biotechnology companies. This series of three videos opens the doors of our company which is dedicated to the regeneration of active drugs in order to develop first class therapies to cure untreated&hellip

Read More

4P-Pharma at BioJapan 2022

4P-Pharma is attending to BioJapan, as a part of french biotechnology company partner with Business France-Santé delegation, from October 12th to 14th in Yokohama, Japan. Meet our CEO, Revital Rattenbach in person during the event.   Keep in touch with Roselina Lam, our Business development and Licensing-in manager to be informed about our portfolio or to discuss&hellip

Read More

4P-Pharma is pleased to welcome Emmanuelle Lopez as our new CFO

4P-Pharma is delighted to welcome Emmanuelle Lopez appointed as a Chief Financial Officer. She has substantial experience and background in both pharma and biotech companies. Emmanuelle Lopez is joining our company at its best time where we are taking an important turn in our growth with the start of our clinical trials. Together, we are&hellip

Read More

4P-Pharma and QuantHealth join forces to conduct AI-based in-Silico clinical trial simulations

4P-Pharma signs a partnership with QuantHealth, a data science start-up taking a unique in-silico approach to clinical trial simulations based on broad real-world data (RWD) and deep molecular drug data. Together, we will conduct in silico clinical trials of our lead drug candidates.​ Our partnership will start with the in-silico simulation of the phase II clinical trial of&hellip

Read More